SERA
Sera Prognostics, Inc. NASDAQ$1.91
After hrs
$1.90
+0.00%
Mkt Cap $91.0M
52w Low $1.37
19.9% of range
52w High $4.09
50d MA $2.10
200d MA $2.82
P/E (TTM)
-2.9x
EV/EBITDA
-3.9x
P/B
1.2x
Debt/Equity
0.0x
ROE
-42.3%
P/FCF
-5.3x
RSI (14)
—
ATR (14)
—
Beta
1.06
50d MA
$2.10
200d MA
$2.82
Avg Volume
51.9K
About
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.17 | -0.16 | +5.9% | 1.91 | -5.8% | -6.3% | -3.7% | -4.7% | +6.3% | +4.2% | +20.4% | — |
| Nov 13, 2025 | AMC | -0.19 | -0.16 | +15.8% | 2.95 | -4.1% | +0.3% | +3.7% | +5.8% | +8.5% | +6.1% | +14.6% | — |
| Aug 6, 2025 | AMC | -0.21 | -0.16 | +23.8% | 2.75 | -6.9% | -5.5% | -9.8% | -14.9% | -18.9% | -16.4% | +21.5% | — |
| May 7, 2025 | AMC | -0.24 | -0.20 | +16.7% | 2.40 | +1.2% | -11.7% | -7.5% | -3.3% | -2.1% | -6.2% | -35.4% | — |
| Mar 19, 2025 | AMC | -0.23 | -0.25 | -8.7% | 4.14 | +1.4% | -5.1% | -8.5% | +0.0% | -2.2% | -5.1% | -18.1% | — |
| Nov 6, 2024 | AMC | -0.22 | -0.24 | -9.1% | 8.74 | +0.0% | -12.7% | -22.9% | -14.9% | -17.2% | -20.3% | -15.9% | — |
| Aug 7, 2024 | AMC | -0.23 | -0.25 | -8.7% | 7.40 | -3.1% | +0.1% | +0.0% | -1.1% | -4.7% | -7.3% | -2.0% | — |
| May 8, 2024 | AMC | -0.23 | -0.25 | -8.7% | 9.30 | -1.0% | +5.3% | -0.4% | -2.2% | -10.2% | -9.4% | -11.9% | — |
| Mar 20, 2024 | AMC | -0.25 | -0.25 | +0.0% | 9.02 | -3.8% | +3.8% | +10.9% | +1.4% | +5.3% | +4.9% | +8.1% | — |
| Nov 8, 2023 | AMC | -0.30 | -0.23 | +23.3% | 1.97 | +1.0% | -7.6% | -14.2% | -10.7% | -12.2% | -14.7% | +120.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10 | Citigroup | Maintains | Neutral → Neutral | — | $2.52 | $2.52 | +0.0% | +3.2% | +0.4% | -7.9% | -13.5% | -18.7% |
| Nov 10 | Citigroup | Maintains | Neutral → Neutral | — | $1.30 | $1.29 | -0.8% | +10.8% | +10.8% | +7.7% | +10.0% | +10.0% |
| Sep 14 | Berenberg | Maintains | Buy → Buy | — | $2.04 | $2.00 | -2.0% | -5.9% | -14.7% | -18.6% | -18.6% | -18.1% |
| Aug 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.18 | $2.10 | -3.7% | -0.5% | +1.4% | -3.7% | -5.0% | -8.3% |
| Apr 27 | Berenberg | Maintains | Buy → Buy | — | $2.23 | $2.59 | +16.1% | +0.9% | -1.8% | +3.1% | +0.9% | -3.6% |
| Mar 30 | Citigroup | Downgrade | Buy → Neutral | — | $4.05 | $3.50 | -13.6% | -7.7% | -6.4% | -10.6% | -13.6% | -19.8% |
| Nov 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.54 | $10.65 | +1.0% | +2.5% | +2.4% | +3.8% | +4.4% | +4.4% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $12.89 | $12.74 | -1.2% | +1.2% | -2.6% | -4.3% | -9.2% | -16.4% |
| Aug 9 | Cowen & Co. | Maintains | Outperform → Outperform | — | $12.89 | $12.74 | -1.2% | +1.2% | -2.6% | -4.3% | -9.2% | -16.4% |
| Aug 9 | William Blair | Maintains | Outperform → Outperform | — | $12.89 | $12.74 | -1.2% | +1.2% | -2.6% | -4.3% | -9.2% | -16.4% |
Recent Filings
Data updated apr 27, 2026 12:46am
· Source: massive.com